GLP-1s are transforming the management of obesity – an area where consumers hold huge sway. Using insights from Ipsos' Consumer Obesity Monitor, assess ongoing anti-obesity medication & GLP-1 demand, track shifts in consumer expectations, and assess the impact of such treatments on their lifestyles.
Through usage of GLP-1s, the obesity treatment landscape is undergoing massive transformation; several associated comorbidities may be next. Consisting of four key modular elements, this report – using Ipsos' Obesity & Cardiometabolic Therapy Monitor data - will help optimise strategies for those with both developmental or commercial interests in this field.
2024's approval of the first indicated drug to treat MASH, coupled with a rich developmental pipeline, sees this landscape on the precipice of change. Consisting of four key modular elements, this report – using Ipsos' MASH Therapy Monitor data - will help optimise strategies for those looking to shape the future of this therapeutic environment.
The treatment of MASH, an advanced form of fatty liver disease, is at a critical juncture. Using physician perceptions from our MASH Future Patient Journey Monitor, this report offers insights into HCP roles, care pathway changes - and the potential impact of out-of-pocket GLP-1 availability.